Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-4.56 Insider Own10.10% Shs Outstand70.77M Perf Week-6.49%
Market Cap889.84M Forward P/E- EPS next Y-3.77 Insider Trans-0.10% Shs Float63.80M Perf Month-9.91%
Income-292.19M PEG- EPS next Q-0.77 Inst Own110.01% Short Float24.34% Perf Quarter-3.24%
Sales0.00M P/S- EPS this Y18.03% Inst Trans-0.98% Short Ratio19.04 Perf Half Y-33.12%
Book/sh6.18 P/B2.03 EPS next Y-2.93% ROA-52.39% Short Interest15.53M Perf Year-37.98%
Cash/sh6.81 P/C1.84 EPS next 5Y- ROE-67.09% 52W Range9.56 - 31.46 Perf YTD-17.23%
Dividend Est.- P/FCF- EPS past 5Y-50.05% ROI-60.82% 52W High-60.14% Beta1.77
Dividend TTM- Quick Ratio7.16 Sales past 5Y-20.00% Gross Margin- 52W Low31.17% ATR (14)1.00
Dividend Ex-Date- Current Ratio7.16 EPS Y/Y TTM-0.81% Oper. Margin0.00% RSI (14)38.88 Volatility5.67% 6.72%
Employees168 Debt/Eq0.10 Sales Y/Y TTM- Profit Margin- Recom1.40 Target Price33.56
Option/ShortYes / Yes LT Debt/Eq0.10 EPS Q/Q7.17% Payout- Rel Volume0.83 Prev Close12.71
Sales Surprise- EPS Surprise-5.87% Sales Q/Q- EarningsFeb 27 BMO Avg Volume815.34K Price12.54
SMA20-12.62% SMA50-9.94% SMA200-29.24% Trades Volume678,124 Change-1.34%
Date Action Analyst Rating Change Price Target Change
Nov-08-23Downgrade Wedbush Outperform → Neutral $38 → $12
Nov-07-23Downgrade Leerink Partners Outperform → Market Perform $15
Jul-12-22Initiated Cowen Outperform
Apr-06-22Initiated Wells Fargo Overweight $67
Oct-07-21Resumed Jefferies Buy $120
Sep-30-21Initiated Stifel Buy $84
Sep-29-21Initiated Oppenheimer Outperform $90
May-21-21Initiated UBS Buy $91
Jan-20-21Initiated Wedbush Outperform $65
Sep-29-20Initiated Cantor Fitzgerald Overweight $44
Apr-02-24 04:05PM
Apr-01-24 05:30PM
Mar-01-24 06:00PM
Feb-28-24 09:55AM
07:01PM Loading…
Feb-27-24 07:01PM
Feb-14-24 09:35AM
Feb-13-24 07:00AM
Feb-08-24 12:00PM
Feb-05-24 11:26PM
Feb-01-24 05:00PM
Jan-25-24 07:00AM
Jan-08-24 07:00AM
Jan-02-24 04:49PM
05:39PM Loading…
Dec-01-23 05:39PM
Nov-13-23 09:03PM
Nov-09-23 07:00AM
Nov-06-23 07:13PM
Nov-01-23 04:52PM
Oct-07-23 05:00AM
Oct-02-23 04:27PM
Sep-14-23 01:02AM
Sep-06-23 07:00AM
Sep-01-23 04:37PM
Aug-09-23 07:00AM
Aug-01-23 04:28PM
Jun-15-23 06:01AM
06:00AM Loading…
Jun-06-23 06:00AM
Jun-02-23 02:34PM
May-26-23 12:33PM
May-25-23 05:38PM
May-23-23 07:00AM
May-12-23 09:55AM
May-10-23 07:00AM
Apr-26-23 10:00AM
Apr-17-23 09:00AM
Mar-01-23 07:00AM
Feb-13-23 07:00AM
Feb-01-23 05:00PM
Jan-17-23 09:18AM
Jan-03-23 05:00PM
Dec-08-22 09:55AM
Dec-01-22 05:00PM
Nov-09-22 07:00AM
Nov-08-22 07:01AM
Nov-01-22 05:38PM
Oct-24-22 07:00AM
Oct-17-22 07:00AM
Oct-03-22 05:32PM
Sep-27-22 04:01PM
Sep-19-22 07:00AM
Sep-12-22 07:00AM
Sep-01-22 05:00PM
Aug-31-22 07:00AM
Aug-26-22 12:00PM
Aug-16-22 09:55AM
Aug-10-22 04:39PM
Aug-09-22 04:01PM
Aug-03-22 07:00AM
Aug-01-22 05:10PM
Jun-27-22 07:00AM
Jun-14-22 09:10AM
Jun-01-22 07:00AM
May-31-22 07:00AM
May-26-22 09:48AM
May-21-22 09:48AM
May-18-22 04:01PM
May-16-22 07:28AM
May-05-22 07:00AM
Apr-27-22 10:17AM
Apr-19-22 09:35AM
Apr-11-22 04:01PM
Apr-08-22 01:00PM
Mar-29-22 07:00AM
Mar-22-22 07:00AM
Mar-09-22 04:01PM
Mar-08-22 04:30PM
Feb-24-22 07:00AM
Feb-03-22 07:00AM
Dec-22-21 10:15AM
Dec-21-21 12:03PM
Dec-14-21 11:15AM
Dec-02-21 07:00AM
Nov-17-21 11:35AM
Nov-10-21 07:00AM
Nov-09-21 07:00AM
Nov-08-21 10:07AM
Nov-03-21 11:26AM
Oct-25-21 12:04PM
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Epperly Melissa B,Chief Financial OfficerFeb 12 '24Sale11.442,57329,435451,449Feb 12 08:22 PM
Gallagher CamPresidentFeb 12 '24Sale11.441,17313,419643,277Feb 12 08:21 PM
Gallagher CamPresidentFeb 02 '24Sale11.5411,552133,310644,450Feb 05 07:13 PM
Epperly Melissa B,Chief Financial OfficerFeb 02 '24Sale11.548,669100,040454,022Feb 05 07:12 PM
Paul AndreaChief Legal OfficerFeb 02 '24Sale11.543,31038,197149,973Feb 05 07:14 PM
Lackner MarkChief Scientific OfficerFeb 02 '24Sale11.541,58518,291195,728Feb 05 07:15 PM
Blackwell KimberlyChief Executive OfficerNov 13 '23Buy10.295,00051,448254,800Nov 13 05:24 PM
Johnson David MichaelDirectorNov 10 '23Buy9.8817,000167,943144,389Nov 13 05:24 PM
Brownstein CarrieChief Medical OfficerOct 04 '23Sale19.5010,628207,298105,685Oct 06 07:19 PM
Bunker Kevin D.Chief Scientific OfficerOct 04 '23Sale19.506,068118,355859,089Oct 06 07:19 PM
Epperly Melissa B,Chief Financial OfficerOct 04 '23Sale19.505,482106,926387,691Oct 06 07:18 PM
Skvarka JanDirectorSep 11 '23Sale25.055,000125,23847,970Sep 13 04:11 PM
Matrix Capital Management Comp10% OwnerJun 20 '23Buy22.664,760,000107,861,60013,959,973Jun 20 04:30 PM
Gallagher CamPresidentMay 31 '23Sale26.2727,768729,506463,502May 31 09:10 PM
Bunker Kevin D.Chief Scientific OfficerMay 26 '23Sale30.0280,0002,401,24815,000May 31 09:09 PM